182 related articles for article (PubMed ID: 20461090)
21. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
23. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
Miyake H; Fujisawa M
Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
[TBL] [Abstract][Full Text] [Related]
24. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of temsirolimus in patients with metastatic renal cell carcinoma.
Levakov I; Vojinov S; Marusic G; Popov M; Levakov O; Popov M; Jeremic D
J BUON; 2016; 21(6):1442-1448. PubMed ID: 28039705
[TBL] [Abstract][Full Text] [Related]
27. Health utility measured with EQ-5D in Thai patients undergoing peritoneal dialysis.
Sakthong P; Kasemsup V
Value Health; 2012; 15(1 Suppl):S79-84. PubMed ID: 22265072
[TBL] [Abstract][Full Text] [Related]
28. Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain; Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, Pfizer, New York, NY; and Bernard Escudier, Institut Gustave Roussy, Villejuif, France.: J Clin Oncol. 2014 Mar 10;32(8):752-9; doi: 10.1200/JCO.2013.50.5305. [Epub 2013 Dec 2].
Trump D
Urol Oncol; 2016 May; 34(5):250-1. PubMed ID: 25937425
[TBL] [Abstract][Full Text] [Related]
29. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
30. Temsirolimus in metastatic renal cell carcinoma.
Négrier S
Ann Oncol; 2008 Aug; 19(8):1369-1370. PubMed ID: 18504249
[No Abstract] [Full Text] [Related]
31. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.
Miyake H; Harada K; Kusuda Y; Fujisawa M
Int J Clin Oncol; 2013 Dec; 18(6):1054-9. PubMed ID: 23114786
[TBL] [Abstract][Full Text] [Related]
34. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
35. Temsirolimus for advanced renal cell carcinoma.
Bergmann L; Maute L; Guschmann M
Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
[TBL] [Abstract][Full Text] [Related]
36. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
37. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
38. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
Alemao E; Rajagopalan S; Yang S; Curiel RE; Purvis J; Al MJ
J Med Econ; 2011; 14(2):245-52. PubMed ID: 21417551
[TBL] [Abstract][Full Text] [Related]
39. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
P J G; A M; L M; H J H; M K; S B; N M
Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
[TBL] [Abstract][Full Text] [Related]
40. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
